Precision medicine in type 2 diabetes: A systematic review of treatment effect heterogeneity for GLP1-receptor agonists and SGLT2-inhibitors.
Young KG, McInnes EH, Massey RJ, Kahkohska AR, Pilla SJ, Raghaven S, Stanislawski MA, Tobias DK, McGovern AP, Dawed AY, Jones AG, Pearson ER, Dennis JM; ADA/EASD Precision Medicine in Diabetes Initiative Consortium.
Young KG, et al.
medRxiv [Preprint]. 2023 Apr 22:2023.04.21.23288868. doi: 10.1101/2023.04.21.23288868.
medRxiv. 2023.
PMID: 37131814
Free PMC article.
Updated.
Preprint.